First Oral Short-course Treatment for Adults with Highly Active Relapsing Multiple Sclerosis Now Approved in Europe

G. Giovannoni
{"title":"First Oral Short-course Treatment for Adults with Highly Active Relapsing Multiple Sclerosis Now Approved in Europe","authors":"G. Giovannoni","doi":"10.17925/ENR.2017.12.02.66","DOIUrl":null,"url":null,"abstract":"Disclosure: Gavin Giovannoni has received compensation for serving as a consultant or speaker for, or has received research support from: AbbVie, Almirall, Atara Bio, Bayer Schering Healthcare, Biogen Idec, Canbex, Eisai, Elan, Fiveprime Therapeutics, Genzyme, Genentech, GlaxoSmithKline, Ironwood Pharmaceuticals, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva Pharmaceutical Industries, UCB and Vertex Pharmaceuticals. This is an expert interview and as such, has not undergone the journal’s standard peer review process.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"12 1","pages":"66"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European neurological review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/ENR.2017.12.02.66","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Disclosure: Gavin Giovannoni has received compensation for serving as a consultant or speaker for, or has received research support from: AbbVie, Almirall, Atara Bio, Bayer Schering Healthcare, Biogen Idec, Canbex, Eisai, Elan, Fiveprime Therapeutics, Genzyme, Genentech, GlaxoSmithKline, Ironwood Pharmaceuticals, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva Pharmaceutical Industries, UCB and Vertex Pharmaceuticals. This is an expert interview and as such, has not undergone the journal’s standard peer review process.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
欧洲批准首个口服短期治疗成人高活度复发性多发性硬化症
披露:Gavin Giovannoni因担任以下公司的顾问或演讲者而获得报酬:AbbVie、Almirall、Atara Bio、Bayer Schering Healthcare、Biogen Idec、Canbex、Eisai、Elan、Fiveprime Therapeutics、Genzyme、Genentech、GlaxoSmithKline、Ironwood Pharmaceuticals、Merck-Serono、Novartis、Pfizer、Roche、Sanofi-Aventis、Synthon BV、Teva Pharmaceutical Industries、UCB和Vertex Pharmaceuticals。这是一次专家访谈,因此没有经过期刊标准的同行评审过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European neurological review
European neurological review Medicine-Neurology (clinical)
自引率
0.00%
发文量
0
期刊最新文献
Autoimmune Encephalitis. Pre-filled Pen for Anti-calcitonin Gene-related Peptide Migraine Therapy Neurological Aspects of the COVID-19 Pandemic Cannabidiol Oral Solution – A New Class of Antiseizure Medication Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1